Severe Asthma Pipeline 2024 | Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera

DelveInsight’s, “Severe Asthma Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Severe Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Severe Asthma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Severe Asthma Pipeline Outlook

 

Key Takeaways from the Severe Asthma Pipeline Report

July 2024:- Incyte Corporation– A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma. The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function
July 2024:- Amgen- A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma. The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
DelveInsight’s Severe Asthma Pipeline analysis depicts a robust space with 50+ active players working to develop 55+ pipeline treatment therapies.
The leading Severe Asthma Companies such as Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
Promising Severe Asthma Therapies such as Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.

 

Stay ahead with the most recent pipeline outlook for Severe Asthma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Severe Asthma Approved Drugs

 

Severe Asthma Emerging Drugs

GSK3511294: GlaxoSmithKline

GSK 3511294, also known as depemokimab, is a long acting, interleukin-5 (IL-5) receptor antagonistic monoclonal antibody, being developed by GlaxoSmithKline, for the treatment of asthma. GSK3511294 is a humanized anti-interleukin (IL)-5 monoclonal antibody (mAb) engineered for extended half-life and improved IL-5 affinity versus other anti-IL-5 mAbs. Currently the drug is in Phase III stage of Clinical trial evaluation for the treatment of severe asthma.

BSI-045B: Biosion

BSI-045B is a high-affinity, humanized monoclonal antibody, targeting thymic stromal lymphopoietin (TSLP), a cytokine that is implicated in the pathogenesis of atopic dermatitis, asthma and other eosinophilic and Th2 immune-related diseases. Biosion’s collaboration partner – CTTQ, a China-based pharmaceutical company with rights to BSI-045B (TQC2731) for China development and commercialization, is currently conducting a Phase II clinical trial of BSI-045B in China for the treatment of severe uncontrolled asthma.

Mepolizumab: Bio-Thera Solutions

Mepolizumab is an interleukin-5 (IL-5) antagonist monoclonal antibody administered subcutaneously via syringe or autoinjector. It is currently indicated for several conditions: as an add-on maintenance treatment for adult and pediatric patients aged six years and older with severe asthma characterized by an eosinophilic phenotype; as an add-on maintenance treatment for adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps; for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis; and for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome of at least six months’ duration without an identifiable non-hematologic secondary cause. Currently the drug is in Phase I stage of its clinical trial for the treatment of severe asthma.

 

Explore groundbreaking therapies and clinical trials in the Severe Asthma Pipeline. Access DelveInsight’s detailed report now! @ Severe Asthma Treatment Drugs

 

Severe Asthma Companies

Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.

 

Severe Asthma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

 

Severe Asthma Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

 

Unveil the future of Severe Asthma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Severe Asthma Market Drivers and Barriers

 

Scope of the Severe Asthma Pipeline Report

Coverage- Global
Severe Asthma Companies- Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera Therapeutics, Suzhou Connect Biopharmaceuticals, Upstream Bio, Teva Branded Pharmaceutical Industries, and others.
Severe Asthma Therapies- Verekitug (UPB-101), FB704A, TQC2731, Benralizumab, povorcitinib, CM326, and others.
Severe Asthma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Severe Asthma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Severe Asthma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Severe Asthma Companies, Key Products and Unmet Needs

 

Table of Content

Introduction
Executive Summary
Severe Asthma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Severe Asthma– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
GSK3511294: GlaxoSmithKline
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BSI-045B: Biosion
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Mepolizumab: Bio-Thera Solutions
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Severe Asthma Key Companies
Severe Asthma Key Products
Severe Asthma- Unmet Needs
Severe Asthma- Market Drivers and Barriers
Severe Asthma- Future Perspectives and Conclusion
Severe Asthma Analyst Views
Severe Asthma Key Companies
Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×